Human SUMO2

Mouse

Human, Rat (tested or 100% immunogen sequence identity)

IgG1,k Monoclonal

SPM621

Unconjugated

Protein G purified

Azide-free, BSA-free. Also available Unmodified.

Recombinant human protein.

Human SUMO2

• IHC
• IHC - Paraffin (0.5 - 1 µg/ml)
• Immunofluorescence (0.5 - 1 µg/ml)
• Flow Cytometry (0.5 - 1 µg/10E6 cells)

The applications listed have been tested for the unmodified form of this product. Other forms have not been tested. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO1 and unlike SUMO1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease. Optimal dilution of the SUMO2 antibody should be determined by the researcher. Staining of formalin/paraffin tissues requires boiling tissue sections in 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min.

1X PBS

Store at 2°C to 8°C.

For research use only. Intended for use by laboratory professionals.

This antibody carries the LSBio 100% Guarantee.

Uniprot: P61956 NCBI: NM_006937 NP_008868.3